The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

In a health alert, the Centers for Disease Control and Prevention and the Food and Drug Administration said people 60 years of age and older should skip getting Valneva-developed Ixchiq vaccine ...

US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it investigates possible side effects. The Centers for Disease Control and Prevention and the Food and ...

Researchers say they've discovered an already approved migraine drug that can stop symptoms hours before a severe headache ...

The French biotech is the first company to bring a chikungunya vaccine to market, getting FDA approval for its Ixchiq (VLA1553) shot in November 2023 and in Europe and Canada in June, for adults ...